Institutional members access full text with Ovid®

Share this article on:

Consequences of Prior Use of Full-dose Ritonavir as Single Protease Inhibitor as Part of Combination Antiretroviral Regimens on the Future Therapy Choices in HIV-1–Infected Children

Feucht, Ute D. MB ChB, FC Paed, MMed, Dip HIV Man, CAHM*; Rossouw, Theresa MB ChB, MPhil, MPH, PhD; Van Dyk, Gisela MSc; Forsyth, Brian MB ChB, FRCP§; Kruger, Mariana MB ChB, MMed, FC Paed, MPhil, PhD

The Pediatric Infectious Disease Journal: February 2014 - Volume 33 - Issue 2 - p e53–e59
doi: 10.1097/INF.0b013e31829f2694
HIV Reports

Background: South African HIV-infected infants below age 6 months and children younger than 3 years on concomitant antimycobacterial treatment received full-dose ritonavir single protease inhibitor (RTV-sPI), together with 2 nucleoside reverse transcriptase inhibitors, from 2004 until 2008. Use of RTV-sPI has been described as a risk factor for PI drug resistance, but the extent of this resistance is unknown.

Aim: This research assesses clinical and virological outcome of a pediatric RTV-sPI cohort at a large South African antiretroviral therapy (ART) site in a high-burden tuberculosis setting, including resistance mutations in those failing ART.

Methods: All children initiated at Kalafong hospital before December 2008, who ever received RTV-sPI–based regimens, were assessed for patient outcome, virological failure and drug resistance. HIV viral loads were done 6-monthly and HIV genotyping since 2009.

Results: There were 178 children who ever received RTV-sPI, with a mean age at ART initiation of 1.4 years. Of the 135 children (76%) with >6 months follow-up, 17 children (13%) never had viral suppression, whereas another 25 (18%) developed virological failure later. Nineteen of 26 children (73%) with genotypic resistance results had major PI mutations.

Conclusions: Treatment failure is not a universal feature in children with prior exposure to RTV-sPI regimens, but the significant proportion (31%) with virological failure is of concern due to high prevalence of major PI- and multiclass mutations. These children currently have no treatment options in the South African public sector, highlighting the urgent need for access to alternative ART regimens to ensure improved outcomes.

From the *Department of Paediatrics, Kalafong Hospital; Department of Family Medicine; Department of Immunology, University of Pretoria, Pretoria, South Africa; §Department of Pediatrics, Yale University, New Haven, CT; and Department of Paediatrics and Child Health, University of Stellenbosch, Tygerberg, South Africa.

Accepted for publication May 22, 2013.

Poster presentation at SA HIV Clinicians Society Conference 2012, Cape Town, South Africa, November 25–28, 2012.

This work was supported by EU grant SANTE 2007 147-790. The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Ute D. Feucht, MB ChB, FC Paed, MMed, Dip HIV Man, CAHM, Department of Pediatrics, Klinikala building, Kalafong Hospital, Private Bag X396, 0001 Pretoria, South Africa. E-mail:

© 2014 by Lippincott Williams & Wilkins, Inc.